Clinical Trials Browser

Not yet recruiting × Uterine Cervical Neoplasms × tislelizumab × Clear all

NCT06039891 2023-09-15

Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms